542 related articles for article (PubMed ID: 21793031)
1. The H4 histamine receptor agonist, clobenpropit, suppresses human cholangiocarcinoma progression by disruption of epithelial mesenchymal transition and tumor metastasis.
Meng F; Han Y; Staloch D; Francis T; Stokes A; Francis H
Hepatology; 2011 Nov; 54(5):1718-28. PubMed ID: 21793031
[TBL] [Abstract][Full Text] [Related]
2. Clobenpropit enhances anti-tumor effect of gemcitabine in pancreatic cancer.
Paik WH; Ryu JK; Jeong KS; Park JM; Song BJ; Lee SH; Kim YT; Yoon YB
World J Gastroenterol; 2014 Jul; 20(26):8545-57. PubMed ID: 25024609
[TBL] [Abstract][Full Text] [Related]
3. H3 or H4 histamine receptors: that which contributes to suppressing human cholangiocarcinoma progression still remains to be clarified.
He GH; Xu GL; Cai WK; Xia W
Hepatology; 2012 Sep; 56(3):1182-3; author reply 1183. PubMed ID: 22371311
[No Abstract] [Full Text] [Related]
4. Fibroblast growth factor receptor 4 promotes progression and correlates to poor prognosis in cholangiocarcinoma.
Xu YF; Yang XQ; Lu XF; Guo S; Liu Y; Iqbal M; Ning SL; Yang H; Suo N; Chen YX
Biochem Biophys Res Commun; 2014 Mar; 446(1):54-60. PubMed ID: 24565842
[TBL] [Abstract][Full Text] [Related]
5. EGF/EGFR axis contributes to the progression of cholangiocarcinoma through the induction of an epithelial-mesenchymal transition.
Clapéron A; Mergey M; Nguyen Ho-Bouldoires TH; Vignjevic D; Wendum D; Chrétien Y; Merabtene F; Frazao A; Paradis V; Housset C; Guedj N; Fouassier L
J Hepatol; 2014 Aug; 61(2):325-32. PubMed ID: 24704591
[TBL] [Abstract][Full Text] [Related]
6. Activation of histamine H4 receptors decreases epithelial-to-mesenchymal transition progress by inhibiting transforming growth factor-β1 signalling pathway in non-small cell lung cancer.
Cai WK; Hu J; Li T; Meng JR; Ma X; Yin SJ; Zhao CH; He GH; Xu GL
Eur J Cancer; 2014 Apr; 50(6):1195-206. PubMed ID: 24447834
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression.
Erice O; Labiano I; Arbelaiz A; Santos-Laso A; Munoz-Garrido P; Jimenez-Agüero R; Olaizola P; Caro-Maldonado A; Martín-Martín N; Carracedo A; Lozano E; Marin JJ; O'Rourke CJ; Andersen JB; Llop J; Gómez-Vallejo V; Padro D; Martin A; Marzioni M; Adorini L; Trauner M; Bujanda L; Perugorria MJ; Banales JM
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1335-1344. PubMed ID: 28916388
[TBL] [Abstract][Full Text] [Related]
8. Enhanced expression of suppresser of cytokine signaling 3 inhibits the IL-6-induced epithelial-to-mesenchymal transition and cholangiocarcinoma cell metastasis.
Zhou QX; Jiang XM; Wang ZD; Li CL; Cui YF
Med Oncol; 2015 Apr; 32(4):105. PubMed ID: 25744243
[TBL] [Abstract][Full Text] [Related]
9. Allicin Inhibits Proliferation and Invasion in Vitro and in Vivo via SHP-1-Mediated STAT3 Signaling in Cholangiocarcinoma.
Chen H; Zhu B; Zhao L; Liu Y; Zhao F; Feng J; Jin Y; Sun J; Geng R; Wei Y
Cell Physiol Biochem; 2018; 47(2):641-653. PubMed ID: 29794468
[TBL] [Abstract][Full Text] [Related]
10. Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma.
Zheng T; Hong X; Wang J; Pei T; Liang Y; Yin D; Song R; Song X; Lu Z; Qi S; Liu J; Sun B; Xie C; Pan S; Li Y; Luo X; Li S; Fang X; Bhatta N; Jiang H; Liu L
Hepatology; 2014 Mar; 59(3):935-46. PubMed ID: 24037855
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of epithelial-mesenchymal transition-related markers according to cell dedifferentiation: clinical implications as an independent predictor of poor prognosis in cholangiocarcinoma.
Ryu HS; Chung JH; Lee K; Shin E; Jing J; Choe G; Kim H; Xu X; Lee HE; Kim DG; Lee H; Jang JJ
Hum Pathol; 2012 Dec; 43(12):2360-70. PubMed ID: 23084587
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin II enhances epithelial-to-mesenchymal transition through the interaction between activated hepatic stellate cells and the stromal cell-derived factor-1/CXCR4 axis in intrahepatic cholangiocarcinoma.
Okamoto K; Tajima H; Nakanuma S; Sakai S; Makino I; Kinoshita J; Hayashi H; Nakamura K; Oyama K; Nakagawara H; Fujita H; Takamura H; Ninomiya I; Kitagawa H; Fushida S; Fujimura T; Harada S; Wakayama T; Iseki S; Ohta T
Int J Oncol; 2012 Aug; 41(2):573-82. PubMed ID: 22664794
[TBL] [Abstract][Full Text] [Related]
13. FTY720 inhibits proliferation and epithelial-mesenchymal transition in cholangiocarcinoma by inactivating STAT3 signaling.
Lu Z; Wang J; Zheng T; Liang Y; Yin D; Song R; Pei T; Pan S; Jiang H; Liu L
BMC Cancer; 2014 Oct; 14():783. PubMed ID: 25344679
[TBL] [Abstract][Full Text] [Related]
14. Nimotuzumab Inhibits Cholangiocarcinoma Cell Metastasis
Padthaisong S; Thanee M; Techasen A; Namwat N; Yongvanit P; Liwatthakun A; Hankla K; Sangkhamanon S; Loilome W
Anticancer Res; 2017 Jul; 37(7):3591-3597. PubMed ID: 28668850
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of membrane metalloendopeptidase inhibits substance P stimulation of cholangiocarcinoma growth.
Meng F; DeMorrow S; Venter J; Frampton G; Han Y; Francis H; Standeford H; Avila S; McDaniel K; McMillin M; Afroze S; Guerrier M; Quezada M; Ray D; Kennedy L; Hargrove L; Glaser S; Alpini G
Am J Physiol Gastrointest Liver Physiol; 2014 May; 306(9):G759-68. PubMed ID: 24603459
[TBL] [Abstract][Full Text] [Related]
16. Hydroxytyrosol inhibits cholangiocarcinoma tumor growth: an in vivo and in vitro study.
Li S; Han Z; Ma Y; Song R; Pei T; Zheng T; Wang J; Xu D; Fang X; Jiang H; Liu L
Oncol Rep; 2014 Jan; 31(1):145-52. PubMed ID: 24247752
[TBL] [Abstract][Full Text] [Related]
17. Mangiferin exerts antitumor activity in breast cancer cells by regulating matrix metalloproteinases, epithelial to mesenchymal transition, and β-catenin signaling pathway.
Li H; Huang J; Yang B; Xiang T; Yin X; Peng W; Cheng W; Wan J; Luo F; Li H; Ren G
Toxicol Appl Pharmacol; 2013 Oct; 272(1):180-90. PubMed ID: 23707762
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-494-dependent WDHDI inhibition suppresses epithelial-mesenchymal transition, tumor growth and metastasis in cholangiocarcinoma.
Liu B; Hu Y; Qin L; Peng XB; Huang YX
Dig Liver Dis; 2019 Mar; 51(3):397-411. PubMed ID: 30314946
[TBL] [Abstract][Full Text] [Related]
19. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice.
Farazi PA; Zeisberg M; Glickman J; Zhang Y; Kalluri R; DePinho RA
Cancer Res; 2006 Jul; 66(13):6622-7. PubMed ID: 16818635
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of cholangiocarcinoma growth by tannic acid.
Marienfeld C; Tadlock L; Yamagiwa Y; Patel T
Hepatology; 2003 May; 37(5):1097-104. PubMed ID: 12717390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
